Clovis Oncology's (CLVS) Price Target Raised to $50 at SunTrust Robinson
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
SunTrust Robinson Humphrey maintained a Buy rating on Clovis Oncology (NASDAQ: CLVS) and raised its price target to $50.00 (from $38.00).
Shares of Clovis Oncology closed at $38.36 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Chardan Capital Markets Starts Clovis Oncology (CLVS) at 'Sell' With Price Target of $15
- Leerink Partners Cuts Price Target on Cynosure (CYNO) Following Solid 3Q
- Jefferies Cuts Price Target on Waters Corp. (WAT) Following Revenue Miss
Create E-mail Alert Related CategoriesAnalyst PT Change
Related EntitiesSunTrust Robinson Humphrey
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!